These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Some factors affecting bioavailability of drug products. Lach JL J Iowa Med Soc; 1972 Aug; 62(8):441-2 passim. PubMed ID: 5044776 [No Abstract] [Full Text] [Related]
25. [The current role of excipients in formulation]. Rochat MH; Verain A Ann Pharm Fr; 1983; 41(6):499-506. PubMed ID: 6677161 [No Abstract] [Full Text] [Related]
26. [Drug dosage form and action]. Zathurecký L Med Klin; 1974 Apr; 69(16):667-70. PubMed ID: 4837397 [No Abstract] [Full Text] [Related]
27. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. Breda SA; Jimenez-Kairuz AF; Manzo RH; Olivera ME Int J Pharm; 2009 Apr; 371(1-2):106-13. PubMed ID: 19150493 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319 [TBL] [Abstract][Full Text] [Related]
29. [Formation of tablets with the aid of chain extensiometry. II. Methodology of formulation]. Delacourte-Thibaut A; Devise B; Guyot JC; Traisnel M J Pharm Belg; 1974; 29(6):489-522. PubMed ID: 4465436 [No Abstract] [Full Text] [Related]
31. [Research of for the discovery of new drugs and research for the development and production of drugs]. Setnikar I Boll Chim Farm; 1971 Sep; 110(9):503-9. PubMed ID: 5137987 [No Abstract] [Full Text] [Related]
32. Assessment of the feasibility of oral controlled release in an exploratory development setting. Thombre AG Drug Discov Today; 2005 Sep; 10(17):1159-66. PubMed ID: 16182208 [TBL] [Abstract][Full Text] [Related]
33. Antiepileptic drug formulation and treatment in the elderly: biopharmaceutical considerations. Gidal BE Int Rev Neurobiol; 2007; 81():299-311. PubMed ID: 17433933 [TBL] [Abstract][Full Text] [Related]
34. [A "new" mechanism behind the hypersensitive reactions to drug combinations. A report from a meeting]. Naess K Tidsskr Nor Laegeforen; 1973 Jan; 93(3):183-4. PubMed ID: 4693379 [No Abstract] [Full Text] [Related]
35. Biopharmaceutics and drug standards. Feldmann EG Am J Hosp Pharm; 1968 Mar; 25(3):111-9. PubMed ID: 5658858 [No Abstract] [Full Text] [Related]
36. Pharmaceutical product development technologies based on the biopharmaceutical classification system. Jain D; Pathak D; Pathak K Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834 [TBL] [Abstract][Full Text] [Related]
38. Does Your Drug Expertise Include Clinical Pharmaceutics? Newton DW Int J Pharm Compd; 2016; 20(3):202-206. PubMed ID: 28333661 [TBL] [Abstract][Full Text] [Related]
39. [Progress in drug technology in the years 1968 and 1969]. Chalabala M; Malý J; Burelová A Cesk Farm; 1970 Nov; 19(9):332-60. PubMed ID: 4926371 [No Abstract] [Full Text] [Related]
40. Formulation of a parenteral antimalarial solution--a French undergraduate project in industrial pharmacy. Jeannin C; Pourcelot Y Am J Pharm Educ; 1977 Feb; 41(1):59-61. PubMed ID: 10236632 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]